Molecular characterization of well-differentiated human thyroid carcinomas by cDNA arrays

International Journal of Oncology

Volumn 29, Issue 5, 2006, Pages 1041-1051

  Zhao, Jianming ^a   Leonard, Christa ^a   Brunner, Erich ^a   Gemsenjäger, Ernst ^b   Heitz, Philipp U ^a   Odermatt, Bernhard ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Hospital of Zollikerberg   (Switzerland)

Author keywords

cDNA array; Follicular thyroid cancer; Gene expression profiling; Papillary thyroid cancer

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MALE; MIDDLE AGED; PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR GENE;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; FEMALE; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; THYROID NEOPLASMS;

EID: 38749097526     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.5.1041     Document Type: Article

References (47)

1. Delellis RA, Lloyd RV, Heitz PU and Eng C: Pathology and genetics of tumours of endocrine organs. In: World Health Organization Classification of Tumors. Kleihues P and Sobin LH (eds). IARC Press, Lyon, p320, 2004.
2. Rosai J, Carcangiu ML and Delellis RA (eds): Tumors of the Thyroid Gland, Third series. AFIP, Washington, DC, 1992.
3. Wynford-Thomas D: Origin and progression of thyroid epithelial tumors: cellular and molecular mechanisms. Horm Res 47: 145-157, 1997.
4. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A and Vecchio G: PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60: 557-563, 1990.
5. Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, Pilotti S, Fusco A, Della Porta G and Pierotti MA: Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 54: 2979-2985, 1994. (Pubitemid 24187783)
6. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM and Fletcher JA: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 289: 1357-1360, 2000. (Pubitemid 30656054)
7. Namba H, Rubin SA and Fagin JA: Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4: 1474-1479, 1990. (Pubitemid 20356608)
8. Suarez HG, Du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C and Monier R: Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5: 565-570, 1990. (Pubitemid 20137069)
9. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627, 2003. (Pubitemid 36553510)
10. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA and Nikiforov YE: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404, 2003. (Pubitemid 37452745)
11. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH and Koeffler HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184, 1993. (Pubitemid 23037270)
12. Zou M, Shi Y and Farid NR: p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 77: 1054-1058, 1993.
13. Jennings T, Bratslavsky G, Gerasimov G, Troshina K, Bronstein M, Dedov I, Alexandrova G and Figge J: Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas. Exp Mol Pathol 62: 199-206, 1995. (Pubitemid 26140109)
14. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD and Saji M: Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61: 6105-6111, 2001. (Pubitemid 32762546)
15. Di Renzo MF, Olivero M, Ferro S, et al: Over-expression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7: 2549-2553, 1992.
16. Chen X, Knauf JA, Gonsky R, Wang M, Lai EH, Chissoe S, Fagin JA and Korenberg JR: From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization. Am J Hum Genet 63: 625-637, 1998. (Pubitemid 30418644)
17. Ward LS, Brenta G, Medvedovic M and Fagin JA: Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab 83: 525-530, 1998.
18. Bauer AJ, Cavalli LR, Rone JD, Francis GL, Burch HB, Tuttle RM, Ringel MD, Stratakis CA and Haddad BR: Evaluation of adult papillary thyroid carcinomas by comparative genomic hybridization and microsatellite instability analysis. Cancer Genet Cytogenet 135: 182-186, 2002.
19. Rodrigues RF, Roque L, Rosa-Santos J, Cid O and Soares J: Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 90: 492-496, 2004.
20. Liotta L and Petricoin E: Molecular profiling of human cancer. Nat Rev Genet 1: 48-56, 2000.
21. Chen KT, Lin JD, Chao TC, Hsueh C, Chang CA, Weng HF and Chan EC: Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid 11: 41-46, 2001.
22. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, Li Volsi V, Frankel W, Kloos RT, Eng C, Pellegata NS and De la Chapelle A: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98: 15044-15049, 2001.
23. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA and Fahey TJ III: Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9: 1792-1800, 2003.
24. Mazzanti C, Zeiger MA, Costourous N, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR and Libutti SK: Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64: 2898-2903, 2004.
25. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R and Singh B: Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64: 3780-3789, 2004.
26. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y and Uchida K: Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10: 2035-2043, 2004.
27. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, De la Chapelle A and Eng C: Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22: 3531-3539, 2004.
28. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL and El-Naggar AK: Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 10: 6586-6597, 2004.
29. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E and Swierniak A: Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65: 1587-1597, 2005.
30. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M and Bidart JM: Follicular thyroid tumors with the PAX8-PPARgamma1 re-arrangement display characteristic genetic alterations. Am J Pathol 167: 223-231, 2005.
31. Hedinger C, Williams ED and Sobin LH: Histological typing of thyroid tumours. In: International Histological Classification of Tumours, 2nd Edition. WHO, Springer-Verlag, Berlin, 1988.
32. Martin KJ, Graner E, Li Y, Price LM, Kritzman BM, Fournier MV, Rhei E and Pardee AB: High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci USA 98: 2646-2651, 2001.
33. Taparowsky E, Shimizu K, Goldfarb M and Wigler M: Structure and activation of the human N-ras gene. Cell 34: 581-586, 1983.
34. Vecchio G and Santoro M: Oncogenes and thyroid cancer. Clin Chem Lab Med 38: 113-116, 2000.
35. Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N and Russo A: Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol 192: 125-130, 2002.
36. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ and Nikiforov YE: Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646-6656, 2005.
37. Finley DJ, Arora N, Zhu B, Gallagher L and Fahey TJ III: Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89: 3214-3223, 2004. (Pubitemid 38951886)
38. Scarpino S, Cancellario d'Alena F, Di Napoli A, Pasquini A, Marzullo A and Ruco LP: Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202: 352-358, 2004.
39. Zhuang Z, Park WS, Pack S, Schmidt L, Vortmeyer AO, Pak E, Pham T, Weil RJ, Candidus S, Lubensky IA, Linehan WM, Zbar B and Weirich G: Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 20: 66-69, 1998.
40. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B and Lee JY: Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59: 307-310, 1999.
41. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867, 2004.
42. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA and Greco A: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23: 7436-7440, 2004.
43. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P and Angeli A: Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58: 3015-3020, 1998.
44. Pasca di Magliano M, Di Lauro R and Zannini M: Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 97: 13144-13149, 2000.
45. Mascia A, Nitsch L, Di Lauro R and Zannini M: Hormonal control of the transcription factor Pax8 and its role in the regulation of thyroglobulin gene expression in thyroid cells. J Endocrinol 172: 163-176, 2002.
46. Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M and Bidart JM: PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol 151: 367-374, 2004.
47. Tan PK, Downey TJ, Spitznagel EL, Jr Xu P, Fu D, Dimitrov DS, Lempicki RA, Raaka BM and Cam MC: Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 31: 5676-5684, 2003.